Abstract Patients with chronic inflammatory diseases are at increased risk of heart failure due to ischemic heart disease and other causes including heart failure with preserved ejection fraction. Using rheumatoid arthritis and treated HIV infection as two prototypical examples, we review the epidemiology of heart failure in these populations and potential therapies to prevent it. Particular focus is given to antiinflammatory therapies including statins and biologic disease-modifying drugs. There is also limited evidence for lifestyle changes and blockade of the renin-angiotensinaldosterone system. We conclude by proposing how a strategy for heart failure prevention, such as the model tested in the Screening To Prevent Heart Failure (STOP-HF) trial, may be adapted to chronic inflammatory disease.
Introduction
Heart Failure Epidemiology and Prevention in the General Population An estimated 5.1 million Americans are living with heart failure (HF), and the prevalence is projected to increase by 25 % by 2030. At the age of 40 years, the life-time risk of developing HF is now an astonishing one in five [1] . The rising prevalence may in part be explained by mortalitylowering therapies for coronary artery disease and systolic HF. For example, in Olmsted County, Minnesota, HF mortality decreased from 57 % to 48 % from 1979 -1984 to 1996 -2000 [2] .
Current strategies to prevent HF focus on managing risk factors among those at highest risk (i.e. those with stage A or stage B disease without clinical symptoms). Intervention strategies include lifestyle modifications (weight loss, exercise, and smoking cessation) and pharmacologic therapy for risk factors (hypertension, diabetes, and dyslipidemia) to reduce the risk of progression to HF [3] . Blockade of the reninangiotensin-aldosterone system (RAAS) is of particular importance. Recently, the Screening To Prevent Heart Failure (STOP-HF) trial demonstrated that such a multilevel screening and treatment strategy can effectively reduce left ventricular (LV) systolic and diastolic dysfunction and incident HF [4••] .
Inflammation in Heart Failure
The role of inflammation in the pathogenesis of HF has been recognized since Elster et al. first noted C-reactive protein (CRP) elevations in the setting of congestive HF in 1956 [5] . Subsequent investigations have confirmed that proinflammatory cytokines and their receptors are elevated in advanced HF, including interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-18 (IL-18), and tumor necrosis factor-α (TNF-α) [6, 7] .
Furthermore, the incidence of cardiovascular disease (CVD), including coronary disease and HF, is increased in patients with comorbid inflammatory disorders, including rheumatoid arthritis (RA) [8] , psoriasis [9] , lupus [10] , and chronic HIV infection [11] . In this review of current literature, we discuss an approach to HF prevention in inflammatory and immune-mediated disease with a focus on RA and HIV infection.
What is the Epidemiology of Heart Failure in Inflammatory and Immune-Mediated Diseases?
Rheumatoid Arthritis
The increased risk of HF in RA may be mediated in part by vascular disease. This includes coronary atherosclerosis and myocardial infarction (MI) as well as effects on vascular compliance, endothelial function, and ventriculovascular interactions. Subclinical atherosclerotic vascular disease appears to be more common in patients with RA than in the general population. Carotid intima-media thickness (cIMT), a surrogate marker of CVD (especially stroke) in the general population [12] , is higher in patients with RA. In a metaanalysis of smaller studies, RA was associated with a cIMT 0.09 mm (95 % CI 0.07 -0.11 mm) higher than in controls [13] . Yet specific RA factors including duration of RA, rheumatoid factor status, and disease activity score (DAS28) were not associated with an increased risk of cIMT [13] . In an alternative approach to carotid artery assessment, Van Sijl et al. reported increases in carotid lumen diameter, circumferential wall stress, and circumferential wall tension in patients with RA, which may indicate a propensity for plaque instability and rupture [14] . Cross-sectional studies have also suggested increased arterial stiffness and endothelial dysfunction in patients with RA [15] ; however, studies have not shown a consistent association between these measures and disease activity [15] .
In addition to vascular disease, RA appears to be associated with subclinical structural heart disease. RA is known to cause rheumatoid nodules that lead to valvular disease (particularly regurgitation), although the severity of valvular lesions is generally less severe than in patients with lupus. A metaanalysis suggested higher odds of aortic stenosis (OR 5.2, 95 % CI 1.1 -24.1), aortic regurgitation (OR 1.7, 95 % CI 1.0 -2.7), mitral regurgitation (OR 3.4, 95 % CI 1.7 -6.7), tricuspid regurgitation (OR 5.3, 95 % CI 2.4 -11.6), and combined valvular lesions (OR 4.3, 95 % CI 2.3 -8.0) [16] . More importantly, inflammatory diseases such as RA may be associated with subclinical myocardial fibrosis and dysfunction. In a recent echocardiography study of patients without significant LV hypertrophy or clinical HF, RA was associated with concentric remodeling and other forms of maladaptive LV geometry (OR 1.44 after adjusting for other CVD factors) [17] . Speckle-tracking strain analyses point to subtle alterations in right ventricular and LV systolic function [18] . Others have found high rates of diastolic dysfunction [19] that is independently associated with disease duration and IL-6 levels.
The Although subclinical disease may be present, the more relevant question is whether RA increases the incidence of clinical stage C and D HF. In a population-based study in Minnesota, Nicola et al. assessed the risk of HF over several decades [8] . At 30 years of follow-up, the cumulative incidence of HF was 34 % in those with RA and 25 % in those without RA. After adjustment for other CVD risk factors, including ischemic heart disease and demographics, patients with RA had almost twice the risk of incident HF (HR 1.87, 95 % CI 1.47 -2.39), and the effect was stronger among those with a positive rheumatoid factor (HR 2.59). Patients with RA in a subsequent study in this cohort were also more likely than non-RA patients to have preserved EF, and had higher 1-year mortality [25] . Finally, several clinical characteristics including elevated erythrocyte sedimentation rate, severe extraarticular manifestations, and corticosteroid use were all associated with HF after adjustment for potential confounders [26] . These findings are compelling but need to be validated in other RA cohorts.
HIV
Since the introduction of effective combination antiretroviral drug therapy (ART) in 1996, the clinical course of chronic HIV infection has been dramatically altered. AIDS is no longer the primary cause of death, but is overshadowed by diseases of aging such as cancer, kidney disease, and CVD. Epidemiologic data suggest that HIV infection is independently associated with about a 1. Prior to effective combination ART, AIDS cardiomyopathy was common and has been well-described [39]; however, the nature of subclinical myocardial disease has changed in the modern treatment era. In an important study using MRI, Holloway et al. The Veterans Administration healthcare system is currently following over 20,000 HIV-infected patients and has provided much of the epidemiologic data regarding the risk of clinical events in this population. HF risk is increased in HIV-infected veterans (adjusted HR 1.8), even when those with coronary disease or alcohol abuse are excluded (adjusted HR 1.96) [11] . The risk is significantly higher among patients with ongoing viral replication compared to those with suppressed viremia on ART. This group has also reported similar risks of HF in patients with reduced versus those with preserved EF [29] .
Observational studies of HIV-infected patients are always limited by the specter of residual confounding because these patients typically have very different risk profiles compared to uninfected control participants. For example, smoking is highly prevalent and other drug use is not always well characterized. Additionally, relatively less is known about HIV-specific risks in women since fewer women are infected and tend not to be well represented in studies. These limitations may be overcome by investigating well-matched cohorts of HIV-infected women and in ongoing studies conducted in sub-Saharan Africa where women are more commonly affected and there is less likelihood of residual confounding.
What is the Role of Risk Factor Management for Heart Failure Prevention in Patients with Rheumatoid Arthritis and HIV?
As in the general population, prevention strategies should target the principle causes of HF, particularly ischemic and hypertensive heart disease. Ischemic heart disease can be reduced by lifestyle modifications, aspirin, and statins.
Exercise
Based primarily on the results of the HF-ACTION trial, the 2013 joint ACC/AHA guidelines for management of HF recommend exercise to improve functional status and reduce hospital readmissions [42] , but it is also likely that exercise prevents HF. In a population of men over 45 years old, selfreported physical activity and sedentary time independently predicted incident HF over 10 years in men without HF at baseline [43] . Less is known, however, about the effect of exercise in patients with RA or HIV infection. A recent clinical trial randomized 40 RA patients to 6 months of supervised aerobic and resistance exercise training versus lifestyle counseling. Aerobic capacity, CVD risk factors, RA disease score, and inflammation all improved significantly in the exercise intervention arm [44] . A subsequent analysis of the same trial reported improvements in microvascular and macrovascular endothelial function [45•]. There were dramatic and clinically relevant improvements in risk factors (for example, a 7 mmHg reduction in systolic BP and doubling of flow-mediated brachial artery dilation), but these results need to be replicated in other studies and the long-term maintenance effects of these interventions on exercise behavior and CVD risk is unknown. In a small pilot trial of HIV-infected patients, a supervised exercise and resistance training program did not improve myocardial insulin sensitivity or LV diastolic function [46] ; although, whether exercise has other effects that lead to decreased clinical HF risk over time is unknown. In patients with RA, 4 weeks of simvastatin 40 mg daily improves endothelial function, particularly among those with the highest levels of systemic inflammation at baseline [51] .
Similarly, 12 weeks of atorvastatin 20 mg daily appears to improve aortic stiffness [52] . A recently published study suggests that statins improve vascular health in mouse models of inflammatory arthritis by decreasing expression of monocyte chemotactic protein-1-induced protein in endothelial cells [53] . In retrospective clinical studies, statin discontinuation appeared to be associated with elevated risk of MI [54] and CVD mortality [55] .
In retrospective studies of HIV-infected patients, statin use was associated with dramatic reductions in total mortality [56, 57] , although there are no prospective clinical trials. Several ongoing trials (clinicaltrials.gov NCT00965185, NCT00673582, NCT01218802 and others) are testing the effect of statins on endothelial function, carotid stiffness and IMT progression, and arterial inflammation, and the results are expected to be reported in 2014.
Hypertension
Treatment of hypertension is one of the most important principles of HF prevention. Yet, there are some antihypertensive agents that have theoretical benefit over others in preventing HF. Inhibition of RAAS with ACE inhibitors, angiotensin receptor blockers, and aldosterone antagonists has antifibrotic and antiinflammatory effects beyond reductions in blood pressure. The increased use of these agents may explain the HF risk reduction observed in the STOP-HF trial.
Initial studies using captopril have suggested that ACE inhibition may have benefit in the treatment of RA [58] ; however, a subsequent study did not show a clinical benefit with the use of pentopril [59] . Some have therefore speculated that having a thiol group is characteristic of ACE inhibitors with clinical benefit [60] . In a mouse model of inflammatory arthritis, ramipril significantly reduced histopathologic synovitis, decreased secondary lesion score, and decreased right hind-paw edema [61•] . In humans, this reduction in generalized inflammation may lead to improved endothelial function as measured by brachial flow-mediated dilation after only 8 weeks of treatment [62] . Longer term effects of ACE inhibition on hard CVD outcomes in RA is unknown.
In the context of chronic HIV infection, the prevalence of hypertension is high and has changed little over time. Furthermore, insufficient control of blood pressure is common [63•] and increases the incidence of cardiovascular events in HIVinfected patients [64] . Telmisartan, an angiotensin II receptor blocker and PPAR-γ receptor agonist, has been studied extensively studied in HIV infection because of its potential pleiotropic effects on the metabolic abnormalities in patients chronically treated with ART. In one study, telmisartan reduced blood pressure, improved lipid metabolism, and improved renal function over 144 weeks. It did not substantially interfere with ART and was well tolerated [65] . It may have further renal protection effects by reducing albuminuria [66] , which was a strong predictor of incident HF in HIV-infected veterans [67] . Because of the important metabolic and body image consequences of subcutaneous lipoatrophy and visceral lipohypertrophy in HIV-infected individuals [68] , the Metabolic Abnormalities, Telmisartan, and HIV infection (MATH) pilot trial was conducted to test the effect of telmisartan on adipose tissue distribution [69] . In this study, 24 weeks of telmisartan reduced total and subcutaneous adipose tissue volumes, but not visceral adipose tissue volumes. Interestingly, there was a reduction in waist circumference and waist:hip ratio, despite no change in BMI or weight. ACE inhibition may also decrease residual inflammation in patients on ART [70] . Similarly to patients with RA, there are no clinical trial data on the effect of RAAS blockade on hard CVD events in patients with chronic HIV infection.
Can Immune-Modulating Agents Prevent Heart Failure?
If chronic inflammation and immune activation are important drivers of HF risk in patients with inflammatory autoimmune diseases or chronic HIV infection, then it is logical that immune therapies may prevent HF. In the case of RA, a wealth of clinical trial level data exist regarding the CVD risk profile of these drugs, and there is proven clinical benefit in RA disease modification. In HIV infection, there is much interest in whether these same drugs may be applied to specific subgroups of patients (i.e. those who fail to reconstitute their CD4+ T-cell count after ART initiation or those with chronically high levels of circulating inflammatory cytokines), but few clinical studies exist.
Methotrexate
Methotrexate (MTX) is the mainstay of RA treatment because it modifies progression of arthritis, but also appears to have a beneficial effect on mortality [71••] . More specifically, in a meta-analysis of observational studies, MTX was associated with 21 % lower total CVD and an 18 % lower risk of MI [72] . MTX may also improve metabolic syndrome parameters, though the evidence is mixed [73] . With regard to HF, there are fewer data, but two studies suggest a potentially strong effect. In an older nested case-control study, diseasemodifying therapies (including MTX) were associated with a 20 % lower risk of incident HF hospitalization [74] . A more recent study found that in patients with RA MTX reduced the risk of HF by half compared to those not receiving MTX [26] .
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized, placebo-controlled trial of the effects of lowdose MTX in preventing cardiovascular events, which will test the inflammation hypothesis of atherothrombosis in the general population [75] . A smaller 24-week study (NCT01949116) is being conducted in parallel to CIRT in a population of HIV-infected patients at high risk of CVD or with residual inflammation on ART. The primary outcome is change in brachial endothelial function. By reducing vascular risk, low-dose MTX has the promise of also reducing HF, though data on clinical outcomes are not likely to be available in the near future.
TNF-α Antagonists
TNF-α antagonists are the most widely used biologic diseasemodifying drugs to treat inflammatory autoimmune diseases, and their CVD risk profiles have been extensively studied. Because of the compelling role of inflammation in HF, clinical trials of anti-TNF therapies to improve HF outcomes in patients without autoimmune disease have been conducted. In the RENEWAL trial, etanercept had no effect on the rate of death or hospitalization, although there was a trend toward worse outcomes in patients with NYHA class IV symptoms [76] . In ATTACH, infliximab was associated with an increased risk of death and HF hospitalization at higher doses, and no clinical benefit at low doses [77] . There have been some concerns about whether these drugs are associated with risk of HF in patients with RA [78] , although a recent large observational study of 11,000 users of anti-TNF-α therapies compared to 9,000 users of nonbiologic disease-modifying antirheumatic drugs (DMARDs) found that anti-TNF-α therapies were not associated with risk of hospitalization for HF [79••] . This lack of association was consistent in multiple subgroup analyses and with varied outcome definitions (new versus recurrent HF hospitalization).
In a recent mechanistic study, an increase in EF, and a reduction in endothelin-1, IL-6 and natriuretic peptides were noted as early as 4 months after initiation of infliximab [80] . There is further evidence that blockade of TNF-α is associated with decreased aortic pulse-wave velocity and decreased aortic inflammation on FDG PET/CT) [81•] . The bulk of data now suggest that TNF-α blockade is at least neutral with regard to incident HF, but should still be avoided in patients with class III or IV symptoms. Mechanistic studies suggest that it may eventually prove to be beneficial for a range of CVD outcomes including HF in patients with RA.
Interleukin-6 Receptor Antagonists
Tocilizumab (TCZ) is a monoclonal antibody targeting the IL-6 receptor that is approved for the treatment of inflammatory arthropathies that may not be responsive to first-line anti-TNF-α therapies. The MEASURE trial evaluated cardiovascular endpoints in patients with RA who received TCZ. Despite slight elevations in low-density lipoprotein (LDL) concentration, there were positive changes toward a more antiinflammatory lipoprotein profile overall as early as 12 weeks after initiation; however, there was a statistically significant increase in aortic stiffness at 12 weeks that was not sustained at 24 weeks [82•] . The effect of TCZ on HF risk is unknown. A trial of TCZ in HIV-infected patients on ART will soon begin enrollment (NCT02049437). The study aims to test whether IL-6 receptor blockade improves immune function by decreasing residual inflammation in this population. Inflammatory lipoproteins and endothelial function will be evaluated as secondary outcomes.
Interleukin-1 Receptor Antagonists
Anakinra, an IL-1 receptor antagonist, is another biologic DMARD that has great potential to decrease HF risk in patients with RA. IL-1 is proinflammatory cytokine with significant negative effects on the vasculature, myocardial responses to ischemia, and both systolic and diastolic function [83] . In patients with RA, a single dose of anakinra improves vascular and LV function and significantly decreases nitrooxidative stress and endothelin [87] . This group subsequently demonstrated improvements in myocardial deformation (systolic and diastolic strains) [88] that are correlated with improvements in soluble markers of apoptosis [89] . Interestingly, these changes are more prominent in those with coronary artery disease than in those without [90••] . There is a recent case report of dramatic clinical improvement after anakinra initiation in a patient with RA and comorbid HF [91] , but large clinical studies of the clinical benefit of anakinra to prevent incident HF are lacking.
Conclusion: Towards a Comprehensive Strategy of Heart Failure Prevention for Chronic Inflammatory Disease
Patients living with chronic inflammatory autoimmune disease or treated HIV infection are at higher risk of clinical HF compared to the general population, and there is an urgent need to develop effective strategies to prevent HF in such high-risk populations. The STOP-HF trial has demonstrated that a concerted multipronged strategy may prevent HF in the general population. How might this strategy be applied in patients with chronic inflammatory diseases? Should there be any important modifications to the approach? Firstly, with regard to selection of at-risk patients, it is likely that brain natriuretic polypeptide will be able to effectively identify RA and HIV patients who would benefit from further imaging (i.e. echocardiography, possibly with speckletracking strain analyses) to identify stage B HF, though the addition of one or more markers of inflammation may prove to be a useful adjunct. Secondly, in addition to proven strategies such as RAAS inhibition for treatment of hypertension, specific antiinflammatory immune therapies could be tailored to at-risk patients. Finally, the role of lifestyle modification and interdisciplinary teams to provide prevention care should not be overlooked.
More data on risk stratification and therapy are needed, however, before such prevention strategies are ready to be tested in clinical trials. In the meantime, rheumatologists and HIV providers should be encouraged to develop a comprehensive approach to CVD risk prevention in their daily practice that includes consultation with cardiovascular specialists who are knowledgeable about the unique risks and management issues in these populations. 
